| Study | Population | Comparators | Costs | Effects | Incr costs | Incr effects | ICER | Uncertainty | Applicability and limitations |
|---|---|---|---|---|---|---|---|---|---|
| Shah et al. 2013 | Patients with invasive early stage breast cancer. | APBRT techniques compared against WBRT - 3D CRT | No deterministic or probabilistic sensitivity analyses were conducted. | The analysis was only partially applicable to the UK context since it considered the US health care system. Serious limitations were identified in the analysis. Most notably, uncertainty around the base case estimates was not assessed as no deterministic or probabilistic sensitivity analyses were conducted. | |||||
| WBRT - 3D CRT | $11,726 | 10.84 | Reference | ||||||
| APBRT - 3D CRT | $6,578 | 10.91 | -$5,148 | 0.07 | Dominant | ||||
| APBRT - IMRT | $10,547 | 10.91 | -$1,179 | 0.07 | Dominant | ||||
| APBRT - SL | $12,602 | 10.91 | $876 | 0.07 | $12,514 per QALY | ||||
| APBRT - ML | $16,439 | 10.91 | $4,713 | 0.07 | $67,329 per QALY | ||||
| APBRT - Interstitial | $11,765 | 10.91 | $39 | 0.07 | $557 per QALY | ||||
| APBI techniques compared against WBRT - IMRT | |||||||||
| WBRT - IMRT | $20,637 | 10.84 | Reference | ||||||
| APBRT - 3D CRT | $6,578 | 10.91 | -$14,059 | 0.07 | Dominant | ||||
| APBRT - IMRT | $10,547 | 10.91 | -$10,090 | 0.07 | Dominant | ||||
| APBRT - SL | $12,602 | 10.91 | -$8,035 | 0.07 | Dominant | ||||
| APBRT - ML | $16,439 | 10.91 | -$4,198 | 0.07 | Dominant | ||||
| APBRT - Interstitial | $11,765 | 10.91 | -$8,872 | 0.07 | Dominant | ||||
|
Comments: Incremental costs and QALYs were not reported in the study. Incremental values above have therefore been estimated as the difference between the absolute values reported in the study. Note also that the study presents costs under numerous scenarios. The costs presented above are for reimbursement costs only as it was thought to best reflect the third party perspective (other scenarios reported in the analysis included ‘non-medical’ costs which possibly include costs more applicable to the societal perspective). | |||||||||
From: Evidence reviews for breast radiotherapy
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.